In contrast, in human medicine, the molecular characterization of thyroid tumor-ascertained mutations in BRAF, NRAS, HRAS, and KRAS is relevant as they are players implicated in thyroid tumor progression through their activation of MAPK- and mTOR-signaling pathways [16,17,18]. This evidence concerns the gene NRAS and thyroid tumor.